Il-1beta Signal Inhibition in acute alcoholic hepatitis: a multicentre, randomised, double-blind, placebo-controlled phase 2 trial of canakinumab therapy (ISAIAH)

N Vergis; VC Patel; K Bogdanowicz; J Czyzewska-Khan; R Keshinro; F Fiorentino; E Day; P Middleton; S Atkinson; M Cross; D Babalis; N Foster; A Quaglia; J Lloyd; RD Goldin; W Rosenberg; R Parker; P Richardson; S Masson; G Whitehouse; C Sieberhagen; D Patch; A Dhanda; E Lord; E Forrest; N Naoumov; M Thursz

doi:10.1016/S0168-8278(22)00480-9

Il-1beta Signal Inhibition in acute alcoholic hepatitis: a multicentre, randomised, double-blind, placebo-controlled phase 2 trial of canakinumab therapy (ISAIAH)

N Vergis, VC Patel, K Bogdanowicz, J Czyzewska-Khan, R Keshinro, F Fiorentino, E Day, P Middleton, S Atkinson, M Cross, D Babalis, N Foster, A Quaglia, J Lloyd, RD Goldin, W Rosenberg, R Parker, P Richardson, S Masson, G WhitehouseC Sieberhagen, D Patch, A Dhanda, E Lord, E Forrest, N Naoumov, M Thursz

Peninsula Medical School

Research output: Contribution to conference › Conference paper (not formally published) › peer-review

Original language	English
DOIs	https://doi.org/10.1016/S0168-8278(22)00480-9
Publication status	Published - 22 Jun 2022

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.1016/S0168-8278(22)00480-9

Cite this

Vergis, N., Patel, VC., Bogdanowicz, K., Czyzewska-Khan, J., Keshinro, R., Fiorentino, F., Day, E., Middleton, P., Atkinson, S., Cross, M., Babalis, D., Foster, N., Quaglia, A., Lloyd, J., Goldin, RD., Rosenberg, W., Parker, R., Richardson, P., Masson, S., ... Thursz, M. (2022). Il-1beta Signal Inhibition in acute alcoholic hepatitis: a multicentre, randomised, double-blind, placebo-controlled phase 2 trial of canakinumab therapy (ISAIAH). https://doi.org/10.1016/S0168-8278(22)00480-9

@conference{21862c45d2ab4431ad77d363c6141a07,

title = "Il-1beta Signal Inhibition in acute alcoholic hepatitis: a multicentre, randomised, double-blind, placebo-controlled phase 2 trial of canakinumab therapy (ISAIAH)",

author = "N Vergis and VC Patel and K Bogdanowicz and J Czyzewska-Khan and R Keshinro and F Fiorentino and E Day and P Middleton and S Atkinson and M Cross and D Babalis and N Foster and A Quaglia and J Lloyd and RD Goldin and W Rosenberg and R Parker and P Richardson and S Masson and G Whitehouse and C Sieberhagen and D Patch and A Dhanda and E Lord and E Forrest and N Naoumov and M Thursz",

year = "2022",

month = jun,

day = "22",

doi = "10.1016/S0168-8278(22)00480-9",

language = "English",

}

Vergis, N, Patel, VC, Bogdanowicz, K, Czyzewska-Khan, J, Keshinro, R, Fiorentino, F, Day, E, Middleton, P, Atkinson, S, Cross, M, Babalis, D, Foster, N, Quaglia, A, Lloyd, J, Goldin, RD, Rosenberg, W, Parker, R, Richardson, P, Masson, S, Whitehouse, G, Sieberhagen, C, Patch, D, Dhanda, A, Lord, E, Forrest, E, Naoumov, N & Thursz, M 2022, 'Il-1beta Signal Inhibition in acute alcoholic hepatitis: a multicentre, randomised, double-blind, placebo-controlled phase 2 trial of canakinumab therapy (ISAIAH)'. https://doi.org/10.1016/S0168-8278(22)00480-9

TY - CONF

T1 - Il-1beta Signal Inhibition in acute alcoholic hepatitis: a multicentre, randomised, double-blind, placebo-controlled phase 2 trial of canakinumab therapy (ISAIAH)

AU - Vergis, N

AU - Patel, VC

AU - Bogdanowicz, K

AU - Czyzewska-Khan, J

AU - Keshinro, R

AU - Fiorentino, F

AU - Day, E

AU - Middleton, P

AU - Atkinson, S

AU - Cross, M

AU - Babalis, D

AU - Foster, N

AU - Quaglia, A

AU - Lloyd, J

AU - Goldin, RD

AU - Rosenberg, W

AU - Parker, R

AU - Richardson, P

AU - Masson, S

AU - Whitehouse, G

AU - Sieberhagen, C

AU - Patch, D

AU - Dhanda, A

AU - Lord, E

AU - Forrest, E

AU - Naoumov, N

AU - Thursz, M

PY - 2022/6/22

Y1 - 2022/6/22

UR - https://www.webofscience.com/api/gateway?GWVersion=2&SrcApp=PARTNER_APP&SrcAuth=LinksAMR&KeyUT=WOS:000826275100054&DestLinkType=FullRecord&DestApp=ALL_WOS&UsrCustomerID=11bb513d99f797142bcfeffcc58ea008

U2 - 10.1016/S0168-8278(22)00480-9

DO - 10.1016/S0168-8278(22)00480-9

M3 - Conference paper (not formally published)

ER -

Il-1beta Signal Inhibition in acute alcoholic hepatitis: a multicentre, randomised, double-blind, placebo-controlled phase 2 trial of canakinumab therapy (ISAIAH)

UN SDGs

Access to Document

Other files and links

Cite this